Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study
- PMID: 24284028
- DOI: 10.1016/j.reprotox.2013.11.004
Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study
Abstract
Objective: To evaluate pregnancy safety of anti-TNF-α medications.
Design: Prospective, comparative, observational study done at the Israeli Teratology Information Service between 2002 and 2011.
Results: 83 anti-TNF-α-exposed-pregnancies (97.6% in the first trimester, T1) were followed-up and compared with 86 disease-matched (DM) and 341 non-teratogenic-exposed (NTE) pregnancies. The anti-TNF-α group consisted of 35 infliximab-, 25 etanercept-, and 23 adalimumab-exposed pregnancies. The rate of major congenital anomalies did not significantly differ between the three groups [3/65 (4.6%) (anti-TNF-α, T1), 5/79 (6.3%) (DM), 8/336 (2.4%) (NTE)], even after excluding genetic or cytogenetic anomalies [3/65 (4.6%) (anti-TNF-α, T1), 4/79 (5.1%) (DM), 6/336 (1.8%) (NTE)]. There were no cases of VATER/VACTERL association.
Conclusion: The present study suggests that anti-TNF-α treatment does not pose a major teratogenic risk in humans. This conclusion is based on relatively small numbers of exposed pregnancies and should be interpreted with caution. Larger studies are needed to establish anti-TNF-α pregnancy safety.
Keywords: Adalimumab; Anti-TNF-α; Autoimmune diseases; Congenital anomalies; Etanercept; Infliximab; Pregnancy.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment.Rheumatology (Oxford). 2014 Jul;53(7):1250-5. doi: 10.1093/rheumatology/keu007. Epub 2014 Mar 5. Rheumatology (Oxford). 2014. PMID: 24599921
-
The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.Int J Clin Pharmacol Ther. 2012 Dec;50(12):867-72. doi: 10.5414/CP201707. Int J Clin Pharmacol Ther. 2012. PMID: 23036238
-
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2. Am J Gastroenterol. 2013. PMID: 23032984
-
TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.Endocr Metab Immune Disord Drug Targets. 2009 Sep;9(3):295-314. doi: 10.2174/187153009789044347. Epub 2009 Sep 1. Endocr Metab Immune Disord Drug Targets. 2009. PMID: 19594416 Review.
-
Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.Rheumatology (Oxford). 2007 Apr;46(4):695-8. doi: 10.1093/rheumatology/kel400. Epub 2006 Dec 7. Rheumatology (Oxford). 2007. PMID: 17158212 Review.
Cited by
-
Real-world pharmacological treatment of pregnant patients with rheumatic diseases from China: a retrospective analysis from 2016 to 2021.Front Pharmacol. 2024 Apr 17;15:1353293. doi: 10.3389/fphar.2024.1353293. eCollection 2024. Front Pharmacol. 2024. PMID: 38694907 Free PMC article.
-
Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review.BMC Pregnancy Childbirth. 2024 Apr 8;24(1):251. doi: 10.1186/s12884-024-06443-w. BMC Pregnancy Childbirth. 2024. PMID: 38589784 Free PMC article.
-
Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.Front Immunol. 2023 Sep 29;14:1206959. doi: 10.3389/fimmu.2023.1206959. eCollection 2023. Front Immunol. 2023. PMID: 37841268 Free PMC article. Review.
-
Drug switching in axial spondyloarthritis patients in Germany - a social listening analysis.Ther Adv Musculoskelet Dis. 2023 Aug 8;15:1759720X231187189. doi: 10.1177/1759720X231187189. eCollection 2023. Ther Adv Musculoskelet Dis. 2023. PMID: 37565049 Free PMC article.
-
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.Rheumatology (Oxford). 2023 Apr 3;62(4):e48-e88. doi: 10.1093/rheumatology/keac551. Rheumatology (Oxford). 2023. PMID: 36318966 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
